A carregar...
Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30‐Expressing Hematologic Malignancies
Brentuximab vedotin, a CD30‐directed antibody‐drug conjugate (ADC), is approved for treating certain patients with CD30‐expressing hematologic malignancies. Its primary mechanism of action is the targeted delivery of a microtubule‐disrupting agent, monomethyl auristatin E (MMAE), to CD30‐expressing...
Na minha lista:
| Publicado no: | J Clin Pharmacol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5574006/ https://ncbi.nlm.nih.gov/pubmed/28513851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.920 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|